A computational study has suggested that phenformin, an oral hypoglycaemic drug, may bind to the active sites of the monoamine oxidase (MAO) A and B enzymes. The present study therefore investigates the MAO inhibitory properties of phenformin. Pentamidine, a structurally related diamidine compound, has previously been reported to be a MAO inhibitor and was included in this study as a reference compound. Using recombinant human MAO-A and MAO-B, this study finds that phenformin acts as a moderately potent MAO-A selective inhibitor with an IC 50 value of 41 µM. Pentamidine, on the other hand, potently inhibits both 
Introduction
Guanidine containing compounds have had a large impact on medicinal chemistry, with pharmacological effects ranging from antimicrobial, antifungal, antiviral and antidiabetic to neurotoxic [1] [2] [3] . Several guanidine containing compounds, such as the antihypertensive drugs, guanadrel and guanethidine, have found therapeutic applications [1, 4] . The guanidine functional group is also found in naturally occurring compounds such as the amino-acid, Larginine. L-arginine is metabolized by the nitric oxide synthases (NOS) to yield L-citruline and nitric oxide (NO) in a two-step reaction [5] . NO is an important physiological mediator that is involved in a large number of signalling processes. Another class of guanidine derivatives is the biguanides, phenformin and metformin, which are used as oral hypoglycaemic drugs in the treatment of type II diabetes mellitus ( Fig. 1) [6] . Phenformin was withdrawn from the US market in 1977 due to an increased incidence of fatal lactic acidosis associated with its use, but it is still available in other countries [6, 7] . The biguanides act by sensitizing peripheral tissues to insulin and by inhibiting hepatic gluconeogenesis [8] . The biguanides are also activators of AMP-activated protein kinase (AMPK), and phenformin is used to examine the role of AMPK in cell signalling pathways [9, 10] . There has been a renewed interest in phenformin as an antineoplastic drug since it has been shown that phenformin exerts antitumor activity in a variety of animal models [11] .
In addition, phenformin and metformin may also enhance the antitumor effects of established chemotherapeutic agents [12, 13] . Using a computational approach, a virtual library of drugs was recently screened for compounds that may bind to the active sites of the monoamine oxidase (MAO) A and B enzymes (unpublished results). The results of these modelling studies suggested that the drug, phenformin, may bind to the MAOs. Based on this, the current study aims to examine the potential MAO-A and MAO-B inhibitory properties of phenformin. For this purpose, the recombinant human MAO enzymes will be employed. Earlier studies reported that a structurally related diamidine compound, pentamidine (an antibiotic in the treatment of
Pneumocystis jirovecii pneumonia and West African trypanosomiasis [14] ), is a potent inhibitor of rabbit and rat liver MAO [15, 16] . Interestingly, pentamidine was found to inhibit rat liver MAO non-competitively and irreversibly [16] . For comparison, the MAO inhibitory properties of pentamidine will be re-examined in this study, with particular emphasis on the reversibility of inhibition. This account will thus investigate, for the first time, the MAO inhibitory properties of pentamidine using the human enzymes. This study will furthermore investigate the selectivity of inhibition of the MAO-A and MAO-B isoforms by pentamidine.
The MAO enzymes are of therapeutic and toxicological importance since they metabolize dietary amines, amine neurotransmitters and amine containing drugs [17] . MAO inhibitors are considered to be useful therapeutic agents: MAO-A inhibitors increase the central levels of serotonin and norepinephrine, and are employed in the therapy of depression [18] , while MAO-B inhibitors elevate the central levels of both endogenous dopamine and dopamine derived from exogenously administered levodopa, and are thus used in the treatment of
Parkinson's disease [19, 20] . Besides central effects, MAO inhibitors also exert peripheral pharmacological actions. When MAO-A inhibitors are combined with tyramine-containing foods, a potentially fatal hypertensive reaction, the "cheese-reaction", may occur [21] . MAO-A catalyzes the first-pass metabolism of tyramine and other sympathomimetic dietary amines and thus prevents them from reaching the systemic circulation. The irreversible inhibition of intestinal MAO-A allows these vasopressor amines to enter the systemic circulation, which in turn may lead to a hypertensive crisis. It should be noted that reversible MAO-A inhibitors, in general, do not precipitate the "cheese-reaction" [22] . A second serious adverse effect of MAO-A inhibition is serotonin toxicity, which is caused by the combination of MAO-A inhibitors and serotonin-releasing agents or selective serotonin reuptake inhibitors [23, 24] . Serotonin toxicity is potentially fatal and is the result of excessive extracellular concentrations of serotonin in the central nervous system. This occurs due to the concurrent inhibition of the MAO-A-catalyzed degradation of serotonin, the inhibition of central serotonin reuptake or the stimulation of serotonin release.
Based on the discussion above, this study examined the human MAO-A and MAO-B inhibitory properties of phenformin and pentamidine in an attempt to evaluate whether the therapeutic and toxicological effects of MAO inhibition should be considered when using these drugs in humans. Even though pentamidine is a known MAO inhibitor, its potencies towards the human MAOs have not been established. In addition, it is not known which MAO isoform is inhibited by pentamidine. This study may also give an indication if the structures of phenformin and pentamidine may serve as leads for the future design of MAO inhibitors. These analyses were carried out with the Prism 5 software package (GraphPad).
Materials and Methods

Materials and instrumentation
IC 50 determinations
The recombinant human enzymes were employed to determine the IC 50 values for the inhibition of MAO-A and MAO-B [26] . The enzymatic reactions were carried out to a final volume of 500 µl and contained the MAO-A/B mixed substrate kynuramine (45 µM for MAO-A and 30 µM for MAO-B) and different concentrations of the test inhibitor (1-1000 µM for phenformin and 0.003-100 µM for pentamidine). Potassium phosphate buffer (100 mM, pH 7.4, made isotonic with KCl) was used as reaction buffer and stock solutions of the test inhibitors were prepared in DMSO and were added to the reactions to yield a final concentration of 4% DMSO. The reactions were initiated with the addition of MAO-A or MAO-B (0.0075 mg protein/ml), incubated for 20 min at 37 ºC and terminated by the addition of 400 µl NaOH (2 N). To each reaction, 1000 µl water was added, and the concentrations of 4-hydroxyquinoline, the MAO-generated oxidation product of kynuramine, were subsequently measured by fluorescence spectrophotometry (λ ex = 310 nm; λ em = 400 nm) [27] . For this purpose linear calibration curves (4-hydroxyquinoline: 0.047-1.56 µM) were constructed. The MAO catalytic rates were calculated and fitted to the one site competition model incorporated into the Prism software package (GraphPad). The IC 50 values were determined in triplicate from the resulting sigmoidal concentration-inhibition curves and are expressed as mean ± SD. (100 mM potassium phosphate, pH 7.4, 5% sucrose). The outer buffer was replaced with fresh buffer at 3 h and 7 h after the start of dialysis. At 24 h after dialysis was started the reactions were diluted twofold with the addition of kynuramine and the residual MAO activities were measured as described above. The final concentration of kynuramine in these reactions was 50 µM while the final inhibitor concentrations were equal to 2 × IC 50 .
Recovery of enzyme activity after dilution
Potassium phosphate buffer (100 mM, pH 7.4, made isotonic with KCl) served as reaction buffer for these reactions. Undialyzed mixtures of the MAOs with phenformin and pentamidine were maintained at 4 °C over the same time period. These reactions were carried out in triplicate and the residual enzyme catalytic rates were expressed as mean ± SD.
The construction of Lineweaver-Burk plots
Sets consisting of five Lineweaver-Burk plots ( Linear regression analysis was performed using Prism 5 [29] . K i values were estimated from the x-axis intercept (-K i ) of a replot of the slopes of the Lineweaver-Burk plots versus inhibitor concentration.
Results
IC 50 values
As mentioned in the introduction, the inhibitory properties of phenformin and pentamidine were investigated using recombinant human MAO-A and MAO-B. To measure the activities of the MAO enzymes, the MAO-A/B mixed substrate, kynuramine, was used as substrate.
The MAO enzymes oxidize kynuramine to yield 4-hydroxyquinoline, as end-product. While kynuramine is a non-fluorescent compound, 4-hydroxyquinoline fluoresces (λ ex = 310 nm;
λ em = 400 nm) in alkaline media and can thus be measured by fluorescence spectrophotometry [27] . At the concentrations and conditions used in this study, phenformin and for the inhibition of MAO-B by lazabemide (Laz) are also provided [30] . 
Reversibility of inhibition
Mode of inhibition
The modes of MAO inhibition by phenformin and pentamidine were further investigated. For this purpose, sets of Lineweaver-Burk plots were constructed. The MAO catalytic activities were recorded at eight substrate concentrations (15-250 µM) in the absence and presence of four different concentrations of the test inhibitors. The plots obtained for pentamidine are given in Fig. 8 and demonstrate that for the inhibition of both MAO-A and MAO-B, the Lineweaver-Burk plots are linear and intersect at a single point. These data suggest that pentamidine most likely interacts competitively and therefore reversibly with the human MAO enzymes. These findings are in contrast to literature which reports that pentamidine acts as an irreversible inhibitor of rat MAO [15, 16] . 
Discussion
This study set out to determine whether the biguanide, phenformin, acts as an inhibitor of the human MAOs. The structurally related diamidine compound, pentamidine, was included in this study since it has been reported to act as a potent MAO inhibitor. As mentioned in the Introduction, even though pentamidine is a known MAO inhibitor [15, 16] , its potencies towards the human MAOs have not been measured. In particular, it has not been established which MAO isoform is inhibited by pentamidine. Based on the report that pentamidine is an irreversible MAO inhibitor, the reversibility of human MAO inhibition by pentamidine was examined.
The results document that phenformin is a moderately potent MAO-A selective inhibitor with an IC 50 value of 40.5 µM. It was also shown that phenformin interacts reversibly with MAO-A.
To evaluate the probability that phenformin may act as a physiological significant MAO-A inhibitor, the plasma levels attained in humans may be considered. Following a single oral dose of 50 mg phenformin hydrochloride to 8 human subjects, plasma levels of 0.33-0.74 µM are obtained [31] . Considering that the IC 50 value for the inhibition of MAO-A is at least 54-fold higher than the plasma levels obtained by phenformin, a pharmacological relevant interaction between MAO-A and phenformin is unlikely. It also does not seem likely that phenformin would accumulate in tissues where MAO-A are found to levels above its IC 50
value.
In contrast to phenformin, pentamidine was found to be a potent MAO-A and MAO-B inhibitor with K i values of 0.41 µM and 0.224 µM, respectively. Pentamidine is a reversible and competitive inhibitor of both human MAO isoforms. This finding is in contrast to literature, which reports that pentamidine acts as an irreversible inhibitor of rabbit and rat liver MAO [15, 16] . An explanation for these different findings is not readily apparent. To evaluate the probability that pentamidine may inhibit MAO-A and MAO-B in the clinical setting, the plasma levels attained in humans should be considered. [21] . Pentamidine may thus, in theory, lead to tyramine-associated hypertensive crisis when combined with tyramine-containing foods. It should however be noted that, in contrast to irreversible MAO-A inhibitors, reversible inhibitors are in general not associated with hypertensive crisis [22] . For example, the reversible MAO-A inhibitor toloxatone, does not elicit tyramine-associated adverse effects when combined with a dose of tyramine consistent with normal food intake [32] . Even though pentamidine inhibits MAO-A, the potentiation of tyramine-induced side effects may be unlikely since this drug acts as a reversible MAO-A inhibitor. The MAO-A inhibitory properties of pentamidine may also be a significance since MAO-A inhibitors may lead to serotonin toxicity when combined with serotonin-releasing agents or selective serotonin reuptake inhibitors [23, 24] . Since pentamidine does not appear to penetrate the central nervous system to a large degree, this compound is not expected to inhibit MAO-A in the brain and thus is not expected precipitate serotonin toxicity when used in conjunction with 5-hydroxytryptaminergic agents [14] .
The inhibition of MAO-B by pentamidine may also be of pharmacological significance. One of the principle functions of MAO-B is to protect neurons from stimulation by the false neurotransmitter, β-phenylethylamine [19, 33] . β-Phenylethylamine is metabolized to a large extent by brain microvessel MAO-B, which limits its entry into the brain [34] . The central levels of β-phenylethylamine, normally present in only trace amounts, may be enhanced several thousand-fold by the administration of MAO-B inhibitors. It may thus be expected that pentamidine may enhance the central levels of β-phenylethylamine by blocking its MAO-B-catalyzed metabolism. Since β-phenylethylamine is both a releaser of dopamine as well as an inhibitor of active dopamine uptake [35] , the blocking of its metabolism results in an increase in striatal extracellular dopamine levels. Pentamidine also may elevate central dopamine levels by inhibiting the MAO-A and MAO-B mediated catabolism of dopamine in the brain. As mentioned above, pentamidine, however, does not appear to penetrate the central nervous system to a large degree. Based on the excellent safety profile of clinically used MAO-B inhibitors, the MAO-B inhibitory properties of pentamidine should not add to its toxicological profile [36] .
To evaluate the contributions of the biguanide and amidine functional groups of phenformin and pentamidine, respectively, to the binding affinities of these drugs for the MAOs, the architectures of the active sites should be considered. The MAO-A and MAO-B active sites are reported to be largely hydrophobic with a polar space in front of the FAD cofactor, the space where the aminyl groups of amine substrates are thought to bind [37] . Polar functional groups of inhibitors are reported to also occupy this space where several hydrogen bond interactions with waters and amino acid residues are possible. For example, the crystal structure of MAO-B in complex with safinamide shows that the propanamidyl moiety binds in proximity to the FAD where the amide group is engaged in hydrogen bonding (Fig. 10 ) [38] .
It is therefore likely that the biguanide and amidine functional groups of phenformin and pentamidine, also bind in proximity to the FAD and thus stabilize the inhibitor via polar compared to irreversible inhibitors [22] . 
